ResearcherKorea Advanced Institute of Science and TechnologyNo recent work listed
Sungwoo Hong
Matched on ORCID iD 0000-0001-9371-1730; OpenAlex author ID A5044287208. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2013: 2 papers · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 2 papers
Papers 8
- Discovery of a novel NUAK1 inhibitor against pancreatic cancer. Co-author DOI 10.1016/j.biopha.2022.113241↗
- A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. Co-author PMID 36225647↗
- Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties. Co-author DOI 10.3390/molecules23102608↗
- HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.12871↗
- Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2014.07.001↗
- HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2435↗
- Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2013.01.007↗
- Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.04.002↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kyung Hee Jung · 7 shared papers, 2013–2022 · strength 0.50
- Paper Discovery of a novel NUAK1 inhibitor against pancreatic cancer. DOI 10.1016/j.biopha.2022.113241↗
- Paper A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. PMID 36225647↗
- Paper HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. DOI 10.18632/oncotarget.12871↗
- Soon‐Sun Hong · 6 shared papers, 2013–2018 · strength 0.32
- Paper Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Pro… DOI 10.3390/molecules23102608↗
- Paper HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. DOI 10.18632/oncotarget.12871↗
- Paper HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. DOI 10.3892/ijo.2014.2435↗
- Soyeon Ko · 2 shared papers, 2022 · strength 0.28
- Soon‐Sun Hong · 2 shared papers, 2022 · strength 0.28
- Mi Kwon Son · 5 shared papers, 2013–2016 · strength 0.22
- Paper HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. DOI 10.18632/oncotarget.12871↗
- Paper HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. DOI 10.3892/ijo.2014.2435↗
- Paper Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. DOI 10.1016/j.canlet.2014.07.001↗
- Hong Hua Yan · 5 shared papers, 2013–2016 · strength 0.22
- Paper HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. DOI 10.18632/oncotarget.12871↗
- Paper HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. DOI 10.3892/ijo.2014.2435↗
- Paper Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. DOI 10.1016/j.canlet.2014.07.001↗
- Zhenghuan Fang · 3 shared papers, 2014–2018 · strength 0.20
- Paper Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Pro… DOI 10.3390/molecules23102608↗
- Paper HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer. DOI 10.18632/oncotarget.12871↗
- Paper HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer. DOI 10.3892/ijo.2014.2435↗
- Myeong-Seong Seo · 1 shared paper, 2022 · strength 0.15
- Ye Jin Cho · 1 shared paper, 2022 · strength 0.13
- Han‐Joo Maeng · 1 shared paper, 2018 · strength 0.10
- Ye-Lim Ryu · 2 shared papers, 2013–2014 · strength 0.08
- Jung Hee Park · 1 shared paper, 2016 · strength 0.05
- Marufa Rumman · 1 shared paper, 2016 · strength 0.05
- Ju Hyeon Seo · 1 shared paper, 2013 · strength 0.04
- Sun‐Mi Yun · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.